Peptide education
Degarelix
Degarelix acetate · Firmagon
Degarelix is a prescription peptide that blocks GnRH receptors in the pituitary. This lowers the hormone signals that drive testosterone production. The US product Firmagon is indicated for advanced prostate cancer and is given as a subcutaneous injection.
Firmagon blocks GnRH receptors to lower testosterone in advanced prostate cancer. Common reactions include injection-site reactions and hot flashes.
Overview
Quick answer
Degarelix blocks the GnRH receptor; leuprolide is an agonist that initially stimulates it. Both can suppress testosterone during continued treatment, but their early hormone responses and injection formulations differ.
What is degarelix used for?
Firmagon is a prescription treatment for advanced prostate cancer. It lowers testosterone as a form of androgen deprivation therapy.
How does it lower testosterone?
It reversibly blocks pituitary GnRH receptors. LH and FSH fall, followed by testosterone.
Is it the same as leuprolide?
No. Degarelix is an antagonist, while leuprolide is an agonist that can initially raise testosterone. In one comparison, testosterone fell sooner with degarelix.
What are the main safety concerns?
Injection-site reactions and hot flashes are common in the label. Serious allergic reactions and QT interval prolongation are warnings, and androgen suppression can affect sexual function and fertility.
Evidence
Evidence snapshot
The estimated rate from day 28 through day 364 was 97.2% with degarelix 240/80 mg and 96.4% with monthly leuprolide. The trial used a non-inferiority comparison for the hormone endpoint.
At day 3, the label reports testosterone at or below 50 ng/dL in 96% of the degarelix 240/80 mg group and 0% of the leuprolide group.
The label reports reactions in 35% of the degarelix group and less than 1% of the leuprolide group. The comparison was open-label and used different injection routes.
Claims
Common claims vs evidence
| Claim | Human evidence | Mechanistic evidence | Verdict |
|---|---|---|---|
| Degarelix lowers testosterone in prostate cancer. | A randomized 12-month trial compared two degarelix schedules with monthly leuprolide in 610 treated patients with prostate cancer at various stages. The primary endpoint was sustained testosterone suppression. | Blocking pituitary GnRH receptors reduces gonadotropin release and subsequently testosterone. | The trial found sustained testosterone suppression, and Firmagon is indicated for advanced prostate cancer. |
| Firmagon can cause injection-site reactions. | In the open-label trial, the Firmagon label reports injection-site reactions in 35% of the degarelix 240/80 mg group and less than 1% of the intramuscular leuprolide group. | Most injection-site reactions were mild or moderate and occurred mainly after the starting dose. The trial used different injection routes for the two treatments. | |
| Degarelix lowered testosterone sooner than leuprolide in the prostate cancer trial. | At day 3, the Firmagon label reports testosterone at or below 50 ng/dL in 96% of the degarelix 240/80 mg group and 0% of the leuprolide group. | At day 28, the label reports testosterone at or below 50 ng/dL in 100% of each group. |
Bottom line
Main takeaway
Degarelix turns down testosterone signals by blocking a pituitary receptor. Firmagon is used for advanced prostate cancer under medical supervision.
Its early testosterone response differs from leuprolide's, but injection reactions, hormone-related effects, and heart-rhythm precautions still matter.
The pivotal comparison measured sustained testosterone at or below 50 ng/dL from day 28 through day 364. It included several prostate cancer stages and an investigational higher maintenance dose.
Identity
What it is
Degarelix is a synthetic ten-amino-acid GnRH antagonist. Firmagon forms a depot after subcutaneous injection and releases the drug into the circulation.
In hormone-sensitive prostate cancer, lowering testosterone reduces a signal that can drive tumor growth. Some prostate cancers continue to grow despite very low testosterone. The US Firmagon label specifies advanced prostate cancer as the indication.
Use context
Routes, doses, and cycle patterns
The Firmagon label specifies a 240 mg starting dose followed by 80 mg every 28 days. The prostate cancer trial also studied a higher 160 mg monthly maintenance dose.
Human studies and product labels
Firmagon starting and maintenance doses
- Purpose
- Treatment of advanced prostate cancer
- Context
- US product label
- Route
- Subcutaneous injection in the abdominal area by a healthcare professional
- Amount
- 240 mg initially as two 120 mg injections, then 80 mg as one injection
- Frequency
- First maintenance dose after 28 days, then every 28 days
- Duration
- Determined in the clinical treatment plan
The starting and maintenance presentations have different strengths and concentrations.
Randomized prostate cancer study, 240/80 mg arm
- Purpose
- Achieving and maintaining testosterone suppression
- Context
- Twelve-month phase 3 comparison
- Route
- Subcutaneous degarelix; intramuscular leuprolide comparator
- Amount
- 240 mg initially, then degarelix 80 mg monthly; comparator leuprolide 7.5 mg monthly
- Frequency
- Monthly after the initial dose
- Duration
- Twelve months of treatment
The reported estimated suppression rate from day 28 through day 364 was 97.2% with degarelix and 96.4% with leuprolide.
Randomized prostate cancer study, 240/160 mg arm
- Purpose
- Investigational comparison of testosterone suppression
- Context
- Study-reported schedule, not the approved Firmagon maintenance dose
- Route
- Subcutaneous injection
- Amount
- 240 mg initially, then 160 mg monthly
- Frequency
- Monthly after the initial dose
- Duration
- Twelve months of treatment
This higher maintenance dose was studied in the trial, but the US Firmagon label states that monthly 160 mg maintenance is not approved.
What varies
- Diagnosis: the Firmagon label specifies advanced prostate cancer, while the trial enrolled patients at various stages.
- Monitoring: the label calls for periodic PSA measurements, testosterone measurement if PSA rises, and additional testosterone checks in hepatic impairment.
- Cardiac context: existing QT problems, heart failure, electrolyte abnormalities, and QT-prolonging medicines affect the risk assessment.
Research
Research evidence
The main comparison was a randomized, open-label study of 610 treated patients with prostate cancer at different stages. It compared two degarelix schedules with monthly leuprolide for testosterone suppression over 12 months. The label specifies that the higher monthly degarelix dose studied is not an approved Firmagon maintenance dose.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| Degarelix versus leuprolide | 610 treated patients with prostate cancer at various stages | Randomized, open-label, 12-month phase 3 trial | Subcutaneous degarelix compared with monthly intramuscular leuprolide | The estimated testosterone suppression rate from day 28 through day 364 was 97.2% for degarelix 240/80 mg and 96.4% for leuprolide. The study reported non-inferiority for its prespecified suppression endpoint. | The trial was open-label and used a biochemical outcome. Disease stages varied, and the finding does not establish a survival or cardiovascular advantage. | Strong for the measured hormone endpoint |
| Early testosterone measurements | Degarelix 240/80 mg and leuprolide groups in the randomized trial | Early laboratory measurements reported in the Firmagon label | Different GnRH antagonist and agonist injection products | At day 3, testosterone was at or below 50 ng/dL in 96% of the degarelix group and 0% of the leuprolide group. | This measurement was taken three days after starting treatment. The main trial endpoint assessed sustained testosterone suppression from day 28 through day 364. | Strong for the reported biochemical measurement |
| Injection-site adverse reactions | Degarelix 240/80 mg and leuprolide groups in the randomized trial | Open-label adverse-reaction reporting in the Firmagon label | Subcutaneous degarelix versus intramuscular leuprolide | Injection-site reactions were reported in 35% and less than 1% of the respective groups. | The treatments used different injection routes and participants knew their assignment. | Product-specific safety evidence |
Cautions
Safety and unknowns
- Injection-site pain, redness, swelling, or firmness, hot flashes, and liver-enzyme increases are among the common reactions described in the Firmagon label.
- Serious hypersensitivity, including anaphylaxis and swelling, has been reported. A history of severe hypersensitivity to degarelix or a product component is a contraindication.
- Androgen deprivation may prolong the QT interval. The label calls for a clinical risk assessment in people with relevant heart conditions, electrolyte abnormalities, or medicines that also prolong QT.
- Low testosterone can affect sexual function, and the label warns about possible fertility impairment and fetal harm. The safety and effectiveness of Firmagon in children are not established.
- Prolonged androgen deprivation can reduce bone density.
- The label advises caution when creatinine clearance is below 50 mL/min because data in moderate or severe kidney impairment are limited. For patients with hepatic impairment, it recommends monthly testosterone monitoring until medical castration is reached; after that, monitoring every other month may be considered. Severe liver dysfunction has not been studied and warrants caution.
Product quality
Product identity and quality
Firmagon is supplied in separate starting-dose and maintenance-dose presentations with different strengths and concentrations.
Starting versus maintenance presentation
The labeled starting dose uses two 120 mg injections; maintenance uses one 80 mg injection, with different product concentrations.
Product and route
The label specifies subcutaneous administration by a healthcare professional in the abdominal area.
Mechanism
How it is proposed to work
Degarelix blocks a pituitary receptor that normally helps signal the testes to produce testosterone. LH and FSH fall, followed by testosterone.
Degarelix binds reversibly to GnRH receptors. It acts as an antagonist, unlike leuprolide, which initially stimulates the receptor before sustained suppression.
In the prostate cancer comparison, testosterone declined earlier with degarelix than with monthly leuprolide. At day 28, the label reports testosterone at or below 50 ng/dL in 100% of each group.
FAQ
Common questions
How is degarelix different from leuprolide?
Degarelix blocks GnRH receptors, while leuprolide stimulates them before sustained exposure suppresses the hormone axis. Their initial testosterone responses differ.
Does faster testosterone suppression prove longer survival?
No. The cited comparison measured testosterone suppression; it does not establish a survival advantage from a faster early response.
Details
Technical details
Sources
References
- 1.
DailyMed. Firmagon prescribing information
US indication, subcutaneous dosing, testosterone response, and safety warnings.
- 2.
PubMed. Degarelix versus leuprolide in prostate cancer: a randomized phase 3 trial
doi:10.1111/j.1464-410X.2008.08183.x PMID:19035858 NCT00295750
A 12-month comparison of testosterone suppression with degarelix and monthly leuprolide.
- 3.
DailyMed. Lupron Depot prescribing information for advanced prostate cancer
Comparator GnRH agonist mechanism, initial testosterone rise, and prostate cancer warnings.
- 4.
National Cancer Institute. Hormone therapy for prostate cancer
Androgen signaling, hormone-sensitive and castration-resistant disease, and GnRH treatment context.